FDA advisory panel backs minimal residual disease as an accelerated approval endpoint for multiple myeloma
Regulation
Product Development
Cullinan raises a $280 million PIPE to develop CLN-978 for lupus
Plus: Intra-Cellular’s Caplyta scores a win in major depressive disorder; and readouts for Marinus, Ultragenyx weigh on shares
Politics, Policy & Law
Congressional Budget Office estimates no cost to taxpayers from Senate version of Biosecure Act
Management Tracks
Plus: Innovent hires Nageatte Ibrahim as oncology CMO, and updates from Endeavor and Vittoria
BioCentury ISSN 1097-7201